华森制药
(002907)
| 流通市值：50.84亿 | | | 总市值：68.74亿 |
| 流通股本：3.09亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 297,078,384.94 | 456,552,929.38 | 271,460,383.5 | 297,753,191.04 |
| 应收票据及应收账款 | 323,172,398.54 | 272,703,800.2 | 301,085,737.88 | 280,010,390.9 |
| 其中：应收票据 | 102,183,107.59 | 97,861,218.9 | 88,042,735.91 | 88,115,033.11 |
| 应收账款 | 220,989,290.95 | 174,842,581.3 | 213,043,001.97 | 191,895,357.79 |
| 预付款项 | 7,324,738.64 | 7,884,495.06 | 5,714,297.89 | 8,375,398.8 |
| 其他应收款合计 | 4,585,305.96 | 2,891,877.67 | 4,468,387.93 | 4,266,954.54 |
| 存货 | 127,823,788.51 | 140,125,411.63 | 149,299,692.71 | 135,589,158.57 |
| 其他流动资产 | 80,871,549.17 | 30,579,915.16 | 81,534,374.64 | 162,759,979.46 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,091,355,563.01 | 1,031,344,511.28 | 1,013,977,367.68 | 958,850,580.15 |
| 非流动资产: | | | | |
| 长期股权投资 | 14,188,853.36 | 15,414,034.45 | 18,570,090.07 | 19,374,769.57 |
| 其他非流动金融资产 | 78,234,500 | 78,234,500 | 72,728,627.97 | 72,933,396.46 |
| 投资性房地产 | 67,054,591.2 | 68,327,959.4 | 68,656,482.27 | 69,477,422.45 |
| 固定资产 | 511,681,804.16 | 527,896,179.7 | 530,437,896.82 | 539,855,482.79 |
| 在建工程 | 10,529,968.44 | 10,190,518.9 | 23,460,639.23 | 23,380,412.81 |
| 使用权资产 | 270,427.16 | 143,168.7 | 144,670.21 | 177,062.98 |
| 无形资产 | 121,085,857.35 | 125,888,406.4 | 123,736,741.26 | 128,367,224.39 |
| 开发支出 | 32,362,755.51 | 30,270,209.78 | 32,586,467.54 | 28,320,349.48 |
| 长期待摊费用 | 6,519,283.04 | 6,699,093.67 | 7,449,833.21 | 7,924,769.89 |
| 递延所得税资产 | 14,922,852.61 | 17,256,757.2 | 14,169,986.85 | 13,543,405.84 |
| 其他非流动资产 | 5,355,936.63 | 5,884,249.52 | 5,797,494.35 | 13,633,944.34 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 862,206,829.46 | 886,205,077.72 | 897,738,929.78 | 916,988,241 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,953,562,392.47 | 1,917,549,589 | 1,911,716,297.46 | 1,875,838,821.15 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 68,465,269.6 | 64,363,225.38 | 73,596,084.42 | 64,902,187.55 |
| 应付账款 | 68,465,269.6 | 64,363,225.38 | 73,596,084.42 | 64,902,187.55 |
| 预收款项 | 946,377.5 | 1,047,147.07 | 1,190,670.23 | 1,268,595.45 |
| 合同负债 | 4,550,742.76 | 8,688,989.46 | 4,119,518.65 | 2,399,364.25 |
| 应付职工薪酬 | 8,013,586.9 | 25,313,927.98 | 7,963,539.76 | 7,752,781.5 |
| 应交税费 | 18,759,671.62 | 11,797,879.99 | 13,207,096.1 | 6,507,348.82 |
| 其他应付款合计 | 108,523,465.25 | 99,573,492.18 | 106,685,525.68 | 106,528,929.16 |
| 一年内到期的非流动负债 | 86,841.42 | 86,841.42 | 105,163.24 | 70,108.83 |
| 其他流动负债 | 598,423.17 | 1,162,637.44 | 664,735.32 | 304,590.96 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 209,944,378.22 | 212,034,140.92 | 207,532,333.4 | 189,733,906.52 |
| 非流动负债: | | | | |
| 租赁负债 | 155,900.21 | 40,720.14 | 44,518.1 | 115,988.01 |
| 递延收益 | 40,906,749.8 | 42,992,848.24 | 45,078,946.68 | 39,535,053.92 |
| 递延所得税负债 | 2,058,277.14 | 2,483,601.32 | 1,783,184.79 | 1,796,584.09 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 43,120,927.15 | 45,517,169.7 | 46,906,649.57 | 41,447,626.02 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 253,065,305.37 | 257,551,310.62 | 254,438,982.97 | 231,181,532.54 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 417,596,314 | 417,596,314 | 417,596,314 | 417,596,314 |
| 资本公积 | 459,480,719.05 | 459,331,051.85 | 459,181,384.65 | 459,031,717.45 |
| 其他综合收益 | 172,255.78 | 178,326.64 | -239,580.56 | 36,131.25 |
| 盈余公积 | 101,260,953.57 | 101,260,953.57 | 92,966,643.89 | 92,966,643.89 |
| 未分配利润 | 721,986,844.7 | 681,631,632.32 | 687,772,552.51 | 675,026,482.02 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,700,497,087.1 | 1,659,998,278.38 | 1,657,277,314.49 | 1,644,657,288.61 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,700,497,087.1 | 1,659,998,278.38 | 1,657,277,314.49 | 1,644,657,288.61 |
| 负债和股东权益合计 | 1,953,562,392.47 | 1,917,549,589 | 1,911,716,297.46 | 1,875,838,821.15 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |